(Total Views: 183)
Posted On: 12/15/2018 10:21:34 AM
Post# of 36569
I’m not reading TC’s post the same as you are. Doom and gloom? Far from so, he’s been quite positive about Generex. You have lots of good stuff going on.
The FDA gave clearance for Excellagen in 2011. Cardium's HCPCS Level II Code Modification Request resulted in the Q code in January 2014. No sales traction.
“We are launching Excellagen® through our direct to physician market channels established with our recently announced acquisitions in pharmacy and management services” -CEO Joe Moscato.
Cardium announced a distribution agreement in 2013 with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals.
I’m not sure why that didn’t gain much traction. Hopefully a main difference is the team, both at Generex, and Anthony Dolisi, CEO of Olaregen. And just as important, an effective vision that Cardium must have lacked.
The FDA gave clearance for Excellagen in 2011. Cardium's HCPCS Level II Code Modification Request resulted in the Q code in January 2014. No sales traction.
“We are launching Excellagen® through our direct to physician market channels established with our recently announced acquisitions in pharmacy and management services” -CEO Joe Moscato.
Cardium announced a distribution agreement in 2013 with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals.
I’m not sure why that didn’t gain much traction. Hopefully a main difference is the team, both at Generex, and Anthony Dolisi, CEO of Olaregen. And just as important, an effective vision that Cardium must have lacked.
(0)
(0)
